Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C P Denton

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
Annals of the Rheumatic Diseases|October 30, 2003
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachD Mukerjee, D St George, B Coleiro, et al.
British Journal of Rheumatology|November 1, 1995
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosisC P Denton, M C Bickerstaff, X Shiwen, et al.
Arthritis and Rheumatism|March 27, 2001
Activation of a fibroblast-specific enhancer of the proalpha2(I) collagen gene in tight-skin miceC P Denton, B Zheng, X Shiwen, et al.
Arthritis and Rheumatism|July 1, 1997
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesisX Shi-Wen, C P Denton, A McWhirter, et al.
The Journal of Biological Chemistry|March 30, 2001
Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) geneT T Antoniv, S De Val, D Wells, et al.
Arthritis and Rheumatism|February 20, 1999
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trialC M Black, A J Silman, A I Herrick, et al.
Rheumatology (Oxford, England)|June 23, 1999
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenonC P Denton, T D Bunce, M B Dorado, et al.
Annals of the Rheumatic Diseases|November 26, 2005
Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from sclerodermaE J Kingdon, A R Mani, M T Frost, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group databaseU A Walker, A Tyndall, L Czirják, et al.
QJM : Monthly Journal of the Association of Physicians|July 3, 2007
Scleroderma renal crisis: patient characteristics and long-term outcomesH Penn, A J Howie, E J Kingdon, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
Annals of the Rheumatic Diseases|October 30, 2003
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachD Mukerjee, D St George, B Coleiro, et al.
British Journal of Rheumatology|November 1, 1995
Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosisC P Denton, M C Bickerstaff, X Shiwen, et al.
Arthritis and Rheumatism|March 27, 2001
Activation of a fibroblast-specific enhancer of the proalpha2(I) collagen gene in tight-skin miceC P Denton, B Zheng, X Shiwen, et al.
Arthritis and Rheumatism|July 1, 1997
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesisX Shi-Wen, C P Denton, A McWhirter, et al.
The Journal of Biological Chemistry|March 30, 2001
Characterization of an evolutionarily conserved far-upstream enhancer in the human alpha 2(I) collagen (COL1A2) geneT T Antoniv, S De Val, D Wells, et al.
Arthritis and Rheumatism|February 20, 1999
Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trialC M Black, A J Silman, A I Herrick, et al.
Rheumatology (Oxford, England)|June 23, 1999
Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenonC P Denton, T D Bunce, M B Dorado, et al.
Annals of the Rheumatic Diseases|November 26, 2005
Low plasma protein nitrotyrosine levels distinguish primary Raynaud's phenomenon from sclerodermaE J Kingdon, A R Mani, M T Frost, et al.
Annals of the Rheumatic Diseases|July 16, 2008
Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group databaseU A Walker, A Tyndall, L Czirják, et al.
QJM : Monthly Journal of the Association of Physicians|July 3, 2007
Scleroderma renal crisis: patient characteristics and long-term outcomesH Penn, A J Howie, E J Kingdon, et al.
Pageof 10